Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease

Journal of Parkinson's Disease

Volumn 1, Issue 4, 2011, Pages 339-346

  Lopez, Sébastien ^a,c   Bonito Oliva, Alessandra ^a   Pallottino, Simone ^a   Acher, Francine ^b   Fisonea, Gilberto ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Basal ganglia; dyskinesia; group III metabotropic glutamate receptors; L DOPA; LSP1 2111; mouse

Indexed keywords

AMPA RECEPTOR; BENSERAZIDE; CYCLIC AMP; LEVODOPA; LSP 1 2111; METABOTROPIC RECEPTOR 4; METABOTROPIC RECEPTOR AGONIST; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; S6 KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DYSKINESIA; LOCOMOTION; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RISK REDUCTION; SIGNAL TRANSDUCTION; STRIATE CORTEX; TREATMENT DURATION;

ADRENERGIC AGENTS; AMINOBUTYRATES; ANIMALS; ANTIPARKINSON AGENTS; BENSERAZIDE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; EXCITATORY AMINO ACID AGONISTS; GENE EXPRESSION REGULATION; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; OXIDOPAMINE; PARKINSON DISEASE; PHOSPHINIC ACIDS; RECEPTORS, METABOTROPIC GLUTAMATE; TIME FACTORS;

EID: 84858174898     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-2011-11066     Document Type: Article

References (44)

1. Birkmayer W, & Hornykiewicz O (1998) The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in Parkinsonism. Parkinsonism Relat Disord, 4, 59-60.
2. Cotzias GC, VanWoert MH, & Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med, 276, 374-379.
3. Mercuri NB, & Bernardi G (2005) The 'magic' of L-dopa: Why is it the gold standard Parkinson's disease therapy? Trends Pharmacol Sci, 26, 341-344.
4. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, & Goetz CG (2007) Levodopa-induced dyskinesias. Mov Disord, 22, 1379-1389; quiz, 1523.
5. Obeso JA, Olanow CW, & Nutt JG (2000) Levodopa motor complications in Parkinson's disease. Trends Neurosci, 23, S2-S7.
6. Snow BJ, Macdonald L, McAuley D, & Wallis W (2000) The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study. Clin Neuropharmacol, 23, 82-85.
7. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, & Onofrj M (2004) Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry, 75, 141-143.
8. Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, & Bonuccelli U (2001) Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study. Mov Disord, 16, 515-520.
9. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, & Chase TN (2000) AMPA receptor blockade improves levodopainduced dyskinesia in MPTP monkeys. Neurology, 54, 1589-1595.
10. Calon F, Grondin R, Morissette M, Goulet M, Blanchet PJ, Di Paolo T, & Bedard PJ (2000) Molecular basis of levodopainduced dyskinesias. Ann Neurol, 47, S70-S78.
11. Conn PJ, Battaglia G, Marino MJ, & Nicoletti F (2005) Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci, 6, 787-798.
12. Conn PJ, & Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol, 37, 205-237.
13. Trombley PQ, & Westbrook GL (1992) L-AP4 inhibits calcium currents and synaptic transmission via a G-protein-coupled glutamate receptor. J Neurosci, 12, 2043-2050.
14. Corti C, Aldegheri L, Somogyi P,&Ferraguti F (2002) Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS. Neuroscience, 110, 403-420.
15. Lebel M, Chagniel L, Bureau G,&CyrM(2010) Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat. Neurobiol Dis, 38, 59-67.
16. Pavon N, Martin AB, Mendialdua A, & Moratalla R (2006) ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry, 59, 64-74.
17. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, HerveD, Greengard P,&FisoneG(2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci, 27, 6995-7005.
18. Westin JE, Vercammen L, Strome EM, Konradi C, & Cenci MA (2007) Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry, 62, 800-810.
19. Darmopil S, Martin AB, De Diego IR, Ares S, & Moratalla R (2009) Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry, 66, 603-613.
20. Feyder M, Bonito-Oliva A, & Fisone G (2011) L-DOPAInduced dyskinesia and abnormal signaling in striatal medium spiny neurons: Focus on dopamine D1 receptor-mediated transmission. Front Behav Neurosci, 5, 71.
21. Santini E, Alcacer C, Cacciatore S, Heiman M, Herve D, Greengard P, Girault JA, Valjent E, & Fisone G (2009) LDOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem, 108, 621-633.
22. Santini E, Heiman M, Greengard P, Valjent E, & Fisone G (2009) Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. Sci Signal, 2, ra36.
23. Fasano S, Bezard E, D'Antoni A, Francardo V, Indrigo M, Qin L, Dovero S, Cerovic M, Cenci MA, & Brambilla R (2010) Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci U S A, 107, 21824-21829.
24. Beurrier C, Lopez S, Revy D, Selvam C, Goudet C, Lherondel M, Gubellini P,Kerkerian-LeGoff L, Acher F, Pin JP,&Amalric M (2009) Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J, 23, 3619-3628.
25. Marino MJ,Williams DL Jr, O'Brien JA, Valenti O, McDonald TP, Clements MK,Wang R, DiLella AG, Hess JF, Kinney GG, & Conn PJ (2003) Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment. Proc Natl Acad Sci U S A, 100, 13668-13673.
26. Lopez S, Turle-Lorenzo N, Acher F, De Leonibus E, Mele A, & Amalric M (2007) Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. J Neurosci, 27, 6701-6711.
27. Austin PJ, Betts MJ, Broadstock M, O'Neill MJ,Mitchell SN, & Duty S (2010) Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease. Br J Pharmacol, 160, 1741-1753.
28. Broadstock M, Austin P, Betts M, & Duty S (2011) Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata. Br J Pharmacol, DOI: 10.1111/ j.1476-5381.2011.01515.x.
29. MacInnes N, Messenger MJ, & Duty S (2004) Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat. Br J Pharmacol, 141, 15-22.
30. Wittmann M, Marino MJ, Bradley SR, & Conn PJ (2001) Activation of group III mGluRs inhibits GABAergic and glutamatergic transmission in the substantia nigra pars reticulata. J Neurophysiol, 85, 1960-1968.
31. Wittmann M, Marino MJ, & Conn PJ (2002) Dopamine modulates the function of group II and group III metabotropic glutamate receptors in the substantia nigra pars reticulata. J Pharmacol Exp Ther, 302, 433-441.
32. Selvam C, Oueslati N, Lemasson IA, Brabet I, Rigault D, Courtiol T, Cesarini S, Triballeau N, Bertrand HO, Goudet C, Pin JP,&Acher FC (2010) A virtual screening hit reveals new possibilities for developing group III metabotropic glutamate receptor agonists. J Med Chem, 53, 2797-2813.
33. Franklin KBJ,&PaxinosG(1997) The Mouse Brain in Stereotaxic Coordinates, Academic Press, San Diego.
34. Lundblad M, Usiello A, Carta M, Hakansson K, Fisone G, & Cenci MA (2005) Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol, 194, 66-75.
35. Towbin H, Staehelin T, & Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA, 76, 4350-4354.
36. Andersson M, Hilbertson A,&CenciMA(1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis, 6, 461-474.
37. Roche KW, O'Brien RJ, Mammen AL, Bernhardt J, & Huganir RL (1996) Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron, 16, 1179-1188.
38. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, & Sibley DR (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science, 250, 1429-1432.
39. Valenti O, Marino MJ,Wittmann M, Lis E, DiLella AG, Kinney GG, & Conn PJ (2003) Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. J Neurosci, 23, 7218-7226.
40. Matsumura M, Tremblay L, Richard H, & Filion M (1995) Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum. Neuroscience, 65, 59-70.
41. Rangel-Barajas C, Silva I, Lopez-SantiagoLM,Aceves J, Erlij D, & Floran B (2011) l-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata. Neurobiol Dis 41, 51-61.
42. Pisani A, Calabresi P, Centonze D, & Bernardi G (1997) Activation of group III metabotropic glutamate receptors depresses glutamatergic transmission at corticostriatal synapse. Neuropharmacology, 36, 845-851.
43. Cuomo D, Martella G, Barabino E, Platania P, Vita D, Madeo G, Selvam C, Goudet C, Oueslati N, Pin JP, Acher F, Pisani A, Beurrier C, Melon C, Kerkerian-Le Goff L, & Gubellini P (2009) Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: Implications for Parkinson's disease treatment. J Neurochem, 109, 1096-1105.
44. Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q, Rodriguez AL, Marlo JE, de Paulis T, Thompson AD, Days EL, Nalywajko T, Austin CA,Williams MB, Ayala JE, Williams R, Lindsley CW, & Conn PJ (2008) Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol, 74, 1345-1358.